FDA Seeks Input on Trippy Ibogaine Trials for Addiction and PTSD
Published Date: 10/6/2026
Notice
Summary
The FDA is asking for public input on how to safely run early clinical trials for ibogaine, a drug being studied to help adults with opioid addiction and PTSD. The government is funding these trials and wants to make sure the study plans cover important safety and care details. Comments are open until November 20, 2026, so anyone interested can share their thoughts before the FDA finalizes its rules.
Analyzed Economic Effects
9 provisions identified: 4 benefits, 5 costs, 0 mixed.
Federal funding and data sharing for ibogaine trials
The Department of Health and Human Services is funding early clinical research on ibogaine through ARPA-H and the National Institute on Drug Abuse, and data from these federally funded programs will be made publicly available to investigators and sponsors. This support is intended to help kick-start early-stage studies in adults with opioid use disorder and adults with PTSD.
Initial dose cap and sequential dosing plan
FDA's initial thinking for an early trial would limit individual doses to not exceed 10 mg/kg and use small, sequential dose-ascending groups with participants dosed one at a time. Dose increases for the next group would occur only after review by a safety review committee, a data and safety monitoring board, and possibly FDA.
Strict cardiac monitoring and inpatient care setting
FDA envisions early ibogaine trials in an inpatient unit with continuous cardiac rhythm monitoring, a physician-led advanced cardiac life support team, a bedside defibrillator, emergency pacing, ventilator support, and monitoring that could last as long as 36 hours after dosing. At least two staff should monitor each participant during acute effects, including one licensed mental health professional.
Eligibility limits and exclusion criteria for participants
Potential participants could be limited to adults 18 to 55 years old and likely excluded if they have structural cardiovascular disease, a baseline QTcF of 430 ms or greater, abnormal heart rate or blood pressure, a history of seizures, psychosis, bipolar disorder, recent suicidal thoughts or behavior, neurodegenerative or balance disorders, significant liver or kidney impairment, or if pregnant or breastfeeding. Low serum potassium, calcium, or magnesium must be corrected before dosing.
Medication restrictions before dosing
Before dosing, participants should stop medications that prolong the QTc interval, slow heart rate, interact with the CYP2D6 enzyme, or raise serotonin. Examples include opioid agonist medications (methadone and buprenorphine), antipsychotics, certain antiemetics, and selective serotonin reuptake inhibitors such as paroxetine and sertraline.
Independent oversight and required expertise
FDA envisions that trials will have a safety review committee (SRC) and an independent data and safety monitoring board (DSMB) that include specialists such as a cardiologist, neurologist, psychiatrist, and biostatistician; trials enrolling people with opioid use disorder should also include an addiction medicine physician. FDA may request to review trial data in certain circumstances.
Study stopping rules for serious events
Dosing should be paused for review if a participant has a sustained ventricular arrhythmia or seizure, a QTc prolongation above 500 ms that persists more than two days, new suicidal thoughts or lasting perceptual disturbances after acute effects, a death or serious adverse event possibly related to ibogaine, or when two or more participants in a group have severe adverse events.
Genotyping and metabolizer-based enrollment
Participants could be genotyped for CYP2D6 and trials may include only fast and intermediate metabolizers, with doses adjusted as needed, because CYP2D6 converts ibogaine to its active metabolite noribogaine.
Product quality and CMC requirements for sponsors
The ibogaine used in trials must be well characterized, include a certificate of analysis, and provide chemistry, manufacturing, and controls (CMC) information as required under 21 CFR 312.23(a)(7).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20441, Medical Devices; Cardiovascular Devices; Classification of the Hyperoxia Monitoring Device Adjunct to Pulse Oximetry
The FDA is officially putting the hyperoxia monitoring device that works with pulse oximeters into a safer, easier-to-manage category called Class II. This change, effective October 6, 2026, means the device will have special safety rules but fewer regulatory hurdles, helping patients get access to this cool tech faster. Medical device makers and healthcare providers will feel the impact, with smoother approval processes and no big new costs expected.
Previous / Next Documents
Previous: 2026-20426, Request for Information: Nationwide Implementation of Prehospital Blood Transfusion
The National Highway Traffic Safety Administration wants your ideas on how to make blood transfusions available before patients reach the hospital, like in ambulances and 911 services. This change could save lives by getting blood to people faster during emergencies across the country. If you have thoughts or experience, share them by November 5, 2026, to help shape this life-saving plan!
Next: 2026-20428, Privacy Act of 1974; System of Records
NARA is updating its records system that tracks requests for workplace accommodations, now including pregnancy and childbirth needs. This change affects current and former employees and job applicants, making the process smoother with a new online tool. Comments on these updates are open until November 5, 2026, and the changes take effect November 16, 2026.